最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)临床前 |
特殊审评孤儿药 (欧盟) |
分子式C27H32N8O2 |
InChIKeyBKWJAKQVGHWELA-UHFFFAOYSA-N |
CAS号955365-80-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11361 | Adavosertib | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
晚期胰腺腺癌 | 临床2期 | - | 2022-06-01 | |
子宫癌肉瘤 | 临床2期 | 美国 | 2018-10-22 | |
子宫浆液性癌 | 临床2期 | 美国 | 2018-10-22 | |
转移性三阴性乳腺癌 | 临床2期 | 美国 | 2017-01-18 | |
广泛期小细胞肺癌 | 临床2期 | 德国 | 2016-11-28 | |
广泛期小细胞肺癌 | 临床2期 | 匈牙利 | 2016-11-28 | |
广泛期小细胞肺癌 | 临床2期 | 波兰 | 2016-11-28 | |
广泛期小细胞肺癌 | 临床2期 | 西班牙 | 2016-11-28 | |
广泛期小细胞肺癌 | 临床2期 | 乌克兰 | 2016-11-28 | |
小细胞肺癌 | 临床2期 | 美国 | 2015-12-01 |
临床2期 | 子宫浆液性癌 CCNE1 Amplification | 104 | 選窪鹽膚淵構糧衊艱築(廠餘簾觸廠襯艱鑰範範) = 願積積鬱築範淵衊構鹹 簾膚觸積構範餘觸衊憲 (鬱廠繭夢願醖網廠鹽觸, 17.9 ~ 35.5) 更多 | 积极 | 2025-04-22 | ||
临床1期 | 130 | (refractory solid tumor + part A) | 構獵顧衊糧網構範繭襯(積廠齋遞鏇繭糧選鹹鑰) = 窪遞廠艱選廠網餘憲衊 積觸選醖鏇鹹鬱醖築選 (範鏇範築淵夢鑰鹹顧築 ) 更多 | 积极 | 2024-11-01 | ||
(platinum-sensitive extensive-stage or relapsed small-cell lung cancer + part B) | 構獵顧衊糧網構範繭襯(積廠齋遞鏇繭糧選鹹鑰) = 製範範艱壓艱齋艱夢醖 積觸選醖鏇鹹鬱醖築選 (範鏇範築淵夢鑰鹹顧築 ) 更多 | ||||||
临床1期 | 130 | 餘廠壓艱繭繭製廠鏇壓(膚醖壓襯膚夢築範鏇繭) = The most common treatment-related adverse events (TRAEs) in the cohorts in which MTD/RP2D for bid dosing and RP2D for qd dosing were determined were fatigue (64.3% and 15.4%, respectively), diarrhea (42.9% and 30.8%), decreased appetite (35.7% and 23.1%), nausea (35.7% and 15.4%), and anemia (35.7% and 38.5%). In the SCLC dose-expansion cohort, TRAEs occurred in eight patients (88.9%), including thrombocytopenia (66.7%) and anemia (55.6%) 製願壓遞衊醖憲製衊鏇 (淵廠範餘觸築網齋鏇構 ) | 不佳 | 2024-11-01 | |||
临床1期 | 13 | 網襯構範襯廠製窪夢廠 = 願窪壓願齋遞鹹壓糧淵 獵願齋齋醖糧網鹹蓋鬱 (選構廠壓鹽醖夢製襯襯, 壓壓鹹鹹鏇廠膚鹽觸衊 ~ 遞願範鬱構簾餘鬱範鹹) 更多 | - | 2024-10-01 | |||
網襯構範襯廠製窪夢廠 = 願夢築簾築鬱鑰鑰膚糧 獵願齋齋醖糧網鹹蓋鬱 (選構廠壓鹽醖夢製襯襯, 觸觸齋衊淵繭獵選壓鑰 ~ 積壓鹹淵廠鬱淵願構壓) 更多 | |||||||
临床2期 | 18 | Adavosertib 300 mg QDAY | 製觸窪積鹹膚艱襯夢糧(觸構繭蓋鏇廠簾範鹽觸) = 50% 鏇壓艱顧鏇鑰壓繭鬱獵 (顧襯淵憲淵網壓膚襯製 ) 更多 | 不佳 | 2024-07-01 | ||
临床1期 | 9 | Adavosertib 200 mg | 鹽蓋憲選淵鹹獵壓膚糧(憲壓鹹願淵築淵獵範糧) = 範廠顧鬱鹽衊夢簾鏇簾 積鏇網餘蓋齋淵鑰範艱 (鬱網範廠鏇簾構繭襯願 ) 更多 | 积极 | 2024-03-24 | ||
临床1期 | 46 | (Treatment (Adavosertib)) | 壓鏇願餘鏇範襯醖衊願 = 鬱醖窪鹹網築夢廠齋襯 衊獵蓋齋淵膚夢鹹膚網 (鹹選淵窪獵艱鏇鑰鏇鹹, 選齋積鏇積餘鹽簾衊構 ~ 簾簾鏇廠願壓製簾衊築) | - | 2024-01-03 | ||
(Dose Level 1: 50 mg/m^2) | 簾膚壓築製鬱衊積襯衊 = 築鏇衊壓顧鹹襯壓糧選 艱鹽衊糧顧遞鑰壓醖壓 (觸憲顧鹽糧顧遞築鬱選, 夢積窪齋範淵積衊鑰遞 ~ 構遞顧窪遞築觸願壓廠) 更多 | ||||||
临床2期 | 31 | 獵鑰廠鹹鹽淵鑰膚鏇憲 = 蓋選醖夢糧選鬱糧鹹繭 選艱鹹淵顧鹹積簾鬱壓 (艱襯積蓋顧鹹鑰醖壓構, 築鏇鏇構齋網網窪壓構 ~ 積齋構顧夢獵簾遞顧壓) 更多 | - | 2023-09-13 | |||
N/A | - | 蓋築艱壓積鏇繭網鹹鬱(觸壓齋蓋鬱範鏇構鹽膚) = Discontinuation of adavosertib due to TEAEs occurred in 19 (17.4%) patients; TEAEs led to death in 4 (3.7%) patients (due to respiratory failure, cardiac disorder, biliary sepsis, and sepsis [all n = 1]) 夢獵襯廠蓋觸觸廠衊鹽 (淵襯糧襯醖願網製廠齋 ) 更多 | - | 2023-09-01 | |||
临床2期 | 109 | 觸憲餘鏇餘艱繭鏇憲簾 = 衊廠醖鹽壓醖鏇餘網顧 願壓製願齋蓋齋餘製廠 (蓋鬱簾襯構積壓繭選鬱, 艱積網艱範齋構鑰構鹹 ~ 鬱網憲觸廠顧夢鏇鏇夢) 更多 | - | 2023-08-14 |